Patents Assigned to Merck
  • QUINAZOLINAMIDE DERIVATIVES
    Publication number: 20110245225
    Abstract: Novel quinazolinamide derivatives of the formula (I), in which R1-R5 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    Type: Application
    Filed: November 12, 2009
    Publication date: October 6, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING
    Inventors: Hans-Michael Eggenweiler, Christian Sirrenberg, Hans-Peter Buchstaller
  • EGFR DEPENDENT MODULATION OF CHEMOKINE EXPRESSION AND INFLUENCE ON THERAPY AND DIAGNOSIS OF TUMORS AND SIDE EFFECTS THEREOF
    Publication number: 20110244506
    Abstract: The invention relates to diagnosis and therapy of tumors utilizing the epidermal growth factor (EGFR) by means of chemical inhibitors or monoclonal antibodies. The invention relates also to skin irritations, preferably skin rash, in conjunction and associated with the treatment of tumor cells that utilize EGF receptor with anti-cancer agents. The invention is also directed to methods of predicting the efficiency of a tumor therapy/tumor response in a patient based on the treatment with EGFR inhibitors, especially anti-EGFR antibodies. The invention further relates to a method of determining the optimum dose of an anti-cancer agent in EGFR related tumor therapy.
    Type: Application
    Filed: January 7, 2011
    Publication date: October 6, 2011
    Applicant: Merck Patent GmbH
    Inventors: Arne Sutter, Joyce Behrens
  • IL-7 FUSION PROTEINS
    Publication number: 20110243887
    Abstract: The invention is directed to a fusion protein which includes a first portion including an immunoglobulin (Ig) chain and a second portion including interleukin-7 (IL-7).
    Type: Application
    Filed: May 18, 2011
    Publication date: October 6, 2011
    Applicant: Merck Patent GmbH
    Inventors: Scott Lauder, Stephen D. Gillies
  • Vaporizing material for producing highly refractive optical layers
    Patent number: 8029923
    Abstract: The invention relates to a vapour-deposition material for the production of optical layers of high refractive index which comprises titanium oxide and gadolinium oxide and/or dysprosium oxide, to a process for the preparation thereof, and to the use thereof.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: October 4, 2011
    Assignee: Merck Patent GmbH
    Inventors: Martin Friz, Reiner Dombrowski, Beate Dombrowski, legal representative, Uwe Anthes
  • Polymer formulations of CETP inhibitors
    Patent number: 8030359
    Abstract: A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: October 4, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sarah Geers, Michael Lowinger, Craig A. McKelvey, Robert F. Meyer, Dina Zhang
  • Potassium channel inhibitors
    Patent number: 8030332
    Abstract: The present invention relates to dipyridin-3-ylmethoxy compounds and derivatives thereof having the structure I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
    Type: Grant
    Filed: January 29, 2007
    Date of Patent: October 4, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: B. Wesley Trotter, Richard C. A. Isaacs, Zhicai Wu, Jacob M. Hoffman, Mark T. Bilodeau, Ahren Iver Green
  • Fused naphthalenes
    Patent number: 8029696
    Abstract: The invention relates to fused naphthalenes of the general formula I, in which A1, A2, A3, A4, Q1-Q2, G1-G2, R1, R2, X1, X2, X3, X4, X5, Z1, Z2, Z3, Z4, q, r, s and t have the meaning indicated, and to the use thereof as components of liquid-crystalline media and to an electro-optical display element containing them.
    Type: Grant
    Filed: July 4, 2007
    Date of Patent: October 4, 2011
    Assignee: Merck Patent GmbH
    Inventors: Holger Kretzschmann, Rudolf Eidenschink
  • EP4 Receptor Agonist, Compositions and Methods Thereof
    Publication number: 20110237511
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: June 3, 2011
    Publication date: September 29, 2011
    Applicant: Merck Frosst Canada
    Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert N. Young
  • RENIN INHIBITORS
    Publication number: 20110237622
    Abstract: The present invention relates to 3,4-substituted piperidinyl—based renin inhibitor compounds bearing at 4-position oxopyridine or Isoquinolone and having the formula (I): wherein S is Formula (IIa) or Formula (IIb). The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: December 8, 2009
    Publication date: September 29, 2011
    Applicant: Merck Frosst Canada LTD.
    Inventors: Austin Chih-Yu Chen, Daniel Dube, Pierre-Andre Fournier, Erich L. Grimm, Patrick Lacombe, Sebastien Laliberte, Dwight Macdonald, D. Bruce Mackay, Daniel James Mckay, Tom Yao-Hsiang Wu
  • CONDUCTIVE POWDER
    Publication number: 20110233482
    Abstract: The present invention relates to an electrically conductive powder which has enough transparency for the use in the field of industrial design requiring expressions by colors, in particular, an electrically conductive powder which has superior dispersibility into solvents or polymer matrixes and gives conductivity even with low PWC. The present invention provides a transparent electrically conductive powder, comprising a first powder component that comprises:(a) a platelet-like aluminum oxide as a first substrate; and (b) a coating layer containing tungsten-doped, or tungsten- and phosphorus-doped, or phosphorus-doped tin oxide wherein the coating layer coats a surface of the first substrate.
    Type: Application
    Filed: August 4, 2008
    Publication date: September 29, 2011
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Tetsuji Honjo, Satoru Kobayashi
  • NOVEL CRYSTALLINE FORMS OF AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
    Publication number: 20110237634
    Abstract: Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole are potent inhibitors of 11?-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.
    Type: Application
    Filed: December 7, 2009
    Publication date: September 29, 2011
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Joseph E. Lynch, Yuri Y. Bereznitski, Frederick T. Mattrey, John L. Leazer, JR., Russell R. Ferlita, Jinchu Liu, Jungjun Yin, Robert M. Wenslow, JR.
  • LIQUID CRYSTALLINE MEDIUM AND LIQUID CRYSTAL DEVICE
    Publication number: 20110234968
    Abstract: The instant invention relates to dielectrically positive nematic media comprising one or more compounds of formula I and one or more compounds of formulae II and III and optionally one or more compounds of formulae IV and V and liquid crystal devices comprising these media and especially to fast switching electro-optical devices.
    Type: Application
    Filed: March 25, 2011
    Publication date: September 29, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Yuko Arai, Takanori Takeda, Yasushi Sugiyama, Hideo Ichinose
  • LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA
    Publication number: 20110233466
    Abstract: The present invention relates to liquid-crystalline compounds having at least three fluorine-substituted benzene rings, a terminal trifluoromethyl group and at least one —CF2O— bridge. The invention also relates to liquid-crystalline media prepared therewith and to liquid-crystal display devices (LC displays) containing these media.
    Type: Application
    Filed: March 22, 2011
    Publication date: September 29, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Axel JANSEN, Helmut Haensel, Philipp Krattiger, Andreas Taugerbeck, Malgorzata Rillich
  • Triazole derivatives as inhibitors of 11-? hydroxysteroid dehydrogenase-1
    Patent number: 8026264
    Abstract: Triazole derivatives of structural formula I are selective inhibitors of the 11?-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: September 27, 2011
    Assignee: Merck Sharp and Dohme Corp.
    Inventors: Sherman T. Waddell, Gina M. Santorelli, Milana M. Maletic, Aaron H. Leeman, Xin Gu, Donald W. Graham, James M. Balkovec, Susan D. Aster
  • Liquid-crystalline medium
    Patent number: 8025935
    Abstract: The invention relates to a liquid-crystalline medium having negative dielectric anisotropy based on a mixture of polar compounds, which comprises at least one compound of the formula I in which R11 and R12 have the meanings indicated in claim 1, in amounts of ?30% by weight, based on the medium, and to the use thereof for an active-matrix display based on the ECB, PALC, FFS or IPS effect.
    Type: Grant
    Filed: August 3, 2006
    Date of Patent: September 27, 2011
    Assignee: Merck Patent GmbH
    Inventors: Melanie Klasen-Memmer, Elisabeth Meyer, Detlef Pauluth, Andreas Taugerbeck
  • Histone deacetylase inhibitors with aryl-pyrazolyl-motifs
    Patent number: 8026260
    Abstract: The present invention relates to a novel class of histone deacetylase inhibitors with aryl-pyrazolyl motifs. The compounds of this invention can be used to treat cancer. The compounds of this invention are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The present invention further provides pharmaceutical compositions comprising the compounds of this invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the compounds of this invention in vivo.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: September 27, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joshua Close, Richard W. Heidebrecht, Jr., Solomon Kattar, Thomas A. Miller, David Sloman, Matthew G Stanton, Paul Tempest, David J. Witter
  • Synthetic gene control region
    Patent number: 8026082
    Abstract: The present invention provides a synthetic gene control region which comprises a gene regulatory sequence comprising a binding site for a gene regulatory protein of a yeast strain, and a promoter from filamentous fungal strain located downstream of the gene regulatory sequence; wherein the promoter can be recognized by the general transcription factors and RNA polymerase of the yeast strain; wherein the gene regulatory sequence is capable of regulating transcription initiated by the filamentous fungal promoter in the yeast strain.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: September 27, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Janine Bryan, Michelle K. Brownlow, Loren D. Schultz, Maria C. Losada, Kathrin Ute Jansen, Myra Kurtz, Stuart Kurtz, legal representative
  • OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20110230518
    Abstract: The invention provides compounds of Formula (I) for the treatment of multiple sclerosis and other diseases.
    Type: Application
    Filed: December 15, 2009
    Publication date: September 22, 2011
    Applicant: MERCK SERONO S.A.
    Inventors: Mathilde Muzerelle, Anna Quattropani, Cyril Montagne, Jérôme Dorbais
  • CO-DOPED 1-1-2 NITRIDES
    Publication number: 20110227475
    Abstract: The invention relates to compounds of the formula (I): (Ca,Sr,Ba)1-x-yMeySiN2:Eux, where Me?Mn2+, Mg2+, Be2+, Ni2+, Co2+ and/or Ru2+; x=0.005 to 0.20; and y<1, and/or of the formula (II): (Ca,Sr,Ba)2-xSi1-zMazN2:Eux, where Ma?Hf4+, Th4+ and/or Zr4+; x=0.005 to 0.
    Type: Application
    Filed: November 2, 2009
    Publication date: September 22, 2011
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Hatfung
    Inventors: Holger Winkler, Ralf Petry, Thomas Vosgroene, Thomas Juestel, Arturas Kastelnikovas, Dominik Uhlich
  • BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN
    Publication number: 20110230471
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R5, D, Z, X, Y, m and p have the meanings indicated in Claim 1, can and be employed for the treatment of tumours.
    Type: Application
    Filed: November 5, 2009
    Publication date: September 22, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Wolfgang Staehle, Ingo Kober, Kai Schiemann, Melanie Schultz, Dirk Wienke